DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Minocycline for HIV+ Cognitive Impairment in Uganda

Information source: Johns Hopkins University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV-associated Cognitive Impairment; HIV Infections

Intervention: minocycline (Drug); minocycline placebo capsule (Drug)

Phase: Phase 1/Phase 2

Status: Terminated

Sponsored by: Johns Hopkins University

Official(s) and/or principal investigator(s):
Ned Sacktor, MD, Principal Investigator, Affiliation: Johns Hopkins School of Medicine

Summary

Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline, an antibiotic, in the treatment of Human immunodeficiency virus (HIV)-associated cognitive impairment in Uganda. Study Design: Treatment, 24-week Randomized, Placebo-Controlled, Double-Blind Phase with Optional 24-week Open Label Phase for Subjects with a cluster of differentiation 4 (CD4) Count in the 251-350 Range

- Arm 1: Minocycline 100 mg orally every 12 hours (50 subjects)

- Arm 2: Matching placebo orally every 12 hours (50 subjects)

Primary Objective: · To examine whether minocycline treatment will improve cognitive performance after 24 weeks compared to baseline Secondary Objectives:

- To examine whether minocycline treatment for 24 weeks is safe and well-tolerated in

individuals with HIV-associated cognitive impairment

- To examine whether minocycline treatment for 48 weeks is safe and well-tolerated in

individuals with HIV-associated cognitive impairment

- To examine whether minocycline treatment for 24 weeks improves functional impairment

Clinical Details

Official title: Minocycline in the Treatment of HIV-Associated Cognitive Impairment in Uganda

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: 24-week Change of Uganda Neuropsychological Test Battery Summary Measure (U NP Sum)

Secondary outcome:

24-week Change of Memorial Sloan Kettering (MSK) HIV Dementia Stage

24-week Change of Karnofsky Performance Score

Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms.

Time From Treatment Initiation to the Development of a Grade ≥ 2 Toxicity and/or Sign and Symptoms

24-week Change of CD4 Cell Counts

48-week Change of CD4 Cell Counts

24-week Change of Instrumental Activities of Daily Living

24-week Change of HIV RNA Plasma Viral Loads (Log10 Transformed)

24-week Change of Center for Epidemiologic Studies Depression (CES-D) Score

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- HIV infection prior to study entry

- Naïve to any antiretroviral regimen and ineligible to receive antiretroviral therapy

by cluster of differentiation 4 (CD4) criteria in Uganda

- Negative serum or urine pregnancy test for women of childbearing potential

- Willingness to use birth control

- Age 18-65 years

- AIDS Dementia Scale Stage 0. 5 OR 1

- Impaired cognitive performance as evidenced by an International HIV Dementia Scale

(HDS) as defined by the protocol

- Ability to sit or stand and swallow intact capsules with an 8-ounce glass of water

- Ability and willingness of subject or legal guardian/ representative to give written

informed consent

- Resident within a 20km radius of Kampala city

Exclusion Criteria:

- Current cancers other than basal cell carcinoma, in situ carcinoma of the cervix, or

Kaposi's sarcoma without evidence of visceral involvement or which does not require systemic chemotherapy

- Severe premorbid psychiatric illness, including schizophrenia and major depression

which, in the in investigator's opinion, is likely to interfere with study compliance

- Active symptomatic AIDS-defining opportunistic infection within 45 days prior to

study entry

- Confounding neurological disorders as defined in the protocol

- Central nervous system infections or cancers as defined in the protocol

- Systemic lupus

- Thyroid disease diagnosed within 24 weeks prior to entry

- Breastfeeding

- Active drug or alcohol use or dependence that, in the opinion of the investigator,

would interfere with adherence to study requirements

- Serious illness requiring systemic treatment and/or hospitalization until subject

either completes therapy or is clinically stable on therapy, in the opinion of the investigator

- History of allergy/sensitivity to minocycline or other tetracyclines and their

formulations

- Any other clinically significant condition or laboratory abnormality that, in the

opinion of the investigator, would interfere with the subject's ability to participate in the study. This includes an individual found to have an HIV dementia scale stage 3 or 4.

- Any esophageal or other condition that would interfere with the swallowing of the

study medication

- Use of excluded drugs as defined by the protocol

Locations and Contacts

Infecious Diseas Institute, Kampala, Uganda
Additional Information

Starting date: April 2008
Last updated: January 28, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017